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The three-dimensional similarity between two fundamental conformations, a dimeric antiparallel extended 
structure and a type I’ p-turn folded form, of enkephalin was examined by computer graphic and empirical 
energy calculation methods. By the rotation of Tyr and Phe side chains, one half of the former structure 
could mimic the three-dimensional form of the latter without a large loss of conformational energy. This 
result provides a new idea for considering the conformation of enkephalin suitable for the multiple opioid 
receptors. The active conformation of enkephalin for ,u- and S-opioid receptors is discussed in the light of 
the present study. 
Enkephatin; B-Turn conformation; Extended dimeric conformation; Energy calculation; Conformational similarity; 
Selectivity 
1. INTRODUCTION 
Pharmacological and biochemical studies of 
opioid peptides have revealed the existence of 
several subdasses of opioid receptors [l-4]. 
Among them, the p- and 6-opioid receptors have 
been most widely discussed. Despite numerous ef- 
forts, however, the structural characteristics of 
opioids suitable for the respective receptors remain 
to be elucidated. 
Recently, the crystal structures of two en- 
dogenous opioid pentapeptides, Met’- and 
Let?-enkephalins, have been analyzed by X-ray 
diffraction methods [5-121, and two different 
forms have been characterized as the fundamental 
conformations of enkephalin: a type I ’ &turn 
folded form and a dimeric antiparallel extended 
structure (see fig.1). These two conformations 
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(A) tB, 
Fig. I. Two fundamental conformations of enkephalin. 
(A) Type I’ B-turn folded form which has two 
intramolecular hydrogen bonds (from (71); (B) a dimeric 
antiparaBe1 extended structure which is stabilized by 
four intermol~ul~ hydrogen bonds (from 1121). 
Structures A and B are denoted as forms I and II in the 
text, respectively. 
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(henceforth denoted as forms I and II, respective- 
ly) have also been suggested to be predominant in 
a solution with a conformational equilibrium [ 131. 
Although it is well known that enkephalin binds 
to both p- and S-receptors [14], it is at present 
unclear whether the same or a different conforma- 
tion of enkephalin binds to these receptors. The 
present report suggests the possibility that either 
form I or II can simultaneously bind to both 
receptors. 
2. METHODS AND PROCEDURES 
Atomic coordinates obtained by X-ray crystal 
analyses were used for this study: form I was built 
from Let?-enkephalin [7] and form II from 
Me?-enkephalin [ 121. As is obvious from fig. 1, the 
width between the antiparallel-running backbone 
chain of form I is almost the same as that of form 
II (4.5 A). To inspect the three-dimensional 
similarity between both forms, therefore, the 
relative dispositions of Tyr’, Phe4 and Met’ or 
Leu’ side chains were considered. The similarity 
was monitored by the three distances 
O(Tyr’)-C,(Gly3), O(Tyr’)-C,(Phe4) and C,- 
(Gly3)-C,(Phe4), where O(Tyr’), C,(Gly3) and 
C,(Phe4) denote the phenolic oxygen atoms of 
Tyr’, C, atom of Gly3 and C, atom of Phe4, 
respectively. These amino acid residues are ab- 
solutely necessary for the activity emergence of 
enkephalin [ 151, 
We attempted to fit the conformation of form II 
to form I by rotation of the Tyr’ and Phe4 side 
chains. Both conformations were then superim- 
posed by the shift of form 1 so as to minimize the 
value of (c; I di)/N, where di is the distance be- 
tween the C, atoms of the i-th residues in both 
forms, and N is the number of residues (= 5). 
The energy change accompanying the rotation 
was calculated by the empirical PPF (partitioned 
potential function) method. The energy functions 
involved in the calculations were nonbonded, elec- 
trostatic and torsional energies, respectively. 
Details of the calculation procedure and the 
parameters used for the calculations have been 
presented in [16]. 
3. RESULTS AND DISCUSSION 
In fig.2 is shown the energy variation accompa- 
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Fig.2. Relative energy of profiles of form II 
accompanying rotation of angle ,$ of Tyr or Phe side 
chains. The profile is represented as the energy 
difference from the energy at x1 = 60” for Tyr, or x1 = 
-40” for Phe, respectively. The arrow indicates the 
torsion angle used for the superimposition. 
nying the rotation ($) about the Cm--CD bond of 
the Tyr’ or Phe4 side chain in form II; the confor- 
mation about the C,+& bond was optimized only 
within + 4” of the value observed in the crystal 
structure, because of the values being nearly equal 
(-89 and 95” for Tyr’ and Phe4 of form I and 
- 89 and - 87” for those of form II, respectively) 
and being in an energetically stable region [ 17,181. 
Fig.2 shows that the rotation about the &-Co 
bond does not significantly make the extended 
dimer structure unstable. A maximum energy gap 
of 1.81 kcal/mol would be compensated by the 
proper external factors such as the interaction with 
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opioid receptors (‘Zipper’ models for Iigand 
binding [19J). The high flexibilities of Tyrr and 
Phe4 side chains, along with those of Met5 or Leu’, 
have also been supposed from the crystal struc- 
tures; these side chains are in the various confor- 
mation states. 
Fig.3 shows the three-dimensional similarity be- 
tween forms I and II, where the former was 
superimposed on the latter. One half of form II is 
nicely fitted to form I of enkephalin, The distances 
O(TY~“)-C,(G~Y~), O(Tyr’)-C;(Phe4) and 
C,(Gly’)-C;(Phe4) are 11.28, 11.75 and 4.60 A for 
form I and 11.80, 10.93 and 5.04 A for form II, 
respectively, and (ci”= I do/N is 1.20 A. Although 
the reIative orientation of each Tyr” aromatic ring 
with respect o its backbone chain is different, the 
positions af phenolic oxygen atoms are almost in 
the same site (the deviation between their oxygen 
atoms is 1.30 A). 
The opioid selectivity for thep-receptor has been 
well discussed, based on the conformational 
Fig.3. Conformational similarity between forms I and 
II. Form I was superimposed on form Il. The Tyr and 
Phe side chains of form I1 were rotated at IO0 intervals 
to fit three relative positions of Tyr, Gly and Phe to 
those of form I (see text). 
similarity between form I of enkephalin and p- 
specific morphine [5,7,13]. On the other hand, the 
conformation of enkeph~in suitabIe for S-opioid 
receptors could be supposed to be form If, as 
judged from the various data; for example, the 
dimerization of p-specific des-Let?-If)-Ala2,Phe- 
NH$enkephalin is converted into the &specific 
form [20,213, and the stable conformation of 6- 
specific deltakephalin is predominantly in an ex- 
tended structure (Ishida, T. et al., in preparation). 
Provided that forms I and II of enkephalin are the 
active conformations for g- and &receptors, 
respectively, the present results imply that form II 
can also interact with theF-receptor, and alternate- 
fy? two enkephalins of form f, which are nearly 
related by a diad symmetry, with the &-receptor; in 
other words, both forms of enkephafin can bind 
simultaneously to /I- and J-receptors. This 
hypothesis can account well for the fact that 
enkephalin analogues with purea or 6 activity have 
not yet been synthesized and, further, why intact 
enkephalin shows activity with p- and &receptors. 
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